Markers of MEK inhibitor resistance in low-grade serous ovarian cancer: EGFR is a potential therapeutic target

BACKGROUND: Although low-grade serous ovarian cancer (LGSC) is rare, case-fatality rates are high as most patients present with advanced disease and current cytotoxic therapies are not overly effective. Recognizing that these cancers may be driven by MAPK pathway activation, MEK inhibitors (MEKi) ar...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Cell Int
Egile Nagusiak: Fernandez, Marta Llaurado, Dawson, Amy, Hoenisch, Joshua, Kim, Hannah, Bamford, Sylvia, Salamanca, Clara, DiMattia, Gabriel, Shepherd, Trevor, Cremona, Mattia, Hennessy, Bryan, Anderson, Shawn, Volik, Stanislav, Collins, Colin C., Huntsman, David G., Carey, Mark S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: BioMed Central 2019
Gaiak:
Primary Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6325847/
https://ncbi.nlm.nih.gov/pubmed/30636931
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12935-019-0725-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak